.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
US Department of Justice
Covington
Johnson and Johnson
McKinsey
McKesson
Healthtrust
Mallinckrodt
QuintilesIMS
Novartis

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018689

« Back to Dashboard
NDA 018689 describes RIDAURA, which is a drug marketed by Sebela Ireland Ltd and is included in one NDA. It is available from two suppliers. Additional details are available on the RIDAURA profile page.

The generic ingredient in RIDAURA is auranofin. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the auranofin profile page.

Summary for 018689

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Immunological Agents
Formulation / Manufacturing:see details

Medical Subject Heading (MeSH) Categories for 018689

Suppliers and Packaging for NDA: 018689

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RIDAURA
auranofin
CAPSULE;ORAL 018689 NDA Sebela Pharmaceuticals Inc. 54766-093 54766-093-06 60 CAPSULE in 1 BOTTLE (54766-093-06)
RIDAURA
auranofin
CAPSULE;ORAL 018689 NDA Prometheus Laboratories Inc. 65483-093 65483-093-06 60 CAPSULE in 1 BOTTLE (65483-093-06)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength3MG
Approval Date:May 24, 1985TE:RLD:Yes

Expired Orange Book Patents for NDA: 018689

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sebela Ireland Ltd
RIDAURA
auranofin
CAPSULE;ORAL018689-001May 24, 1985► Subscribe► Subscribe
Sebela Ireland Ltd
RIDAURA
auranofin
CAPSULE;ORAL018689-001May 24, 1985► Subscribe► Subscribe
Sebela Ireland Ltd
RIDAURA
auranofin
CAPSULE;ORAL018689-001May 24, 1985► Subscribe► Subscribe
Sebela Ireland Ltd
RIDAURA
auranofin
CAPSULE;ORAL018689-001May 24, 1985► Subscribe► Subscribe
Sebela Ireland Ltd
RIDAURA
auranofin
CAPSULE;ORAL018689-001May 24, 1985► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Daiichi Sankyo
Accenture
Federal Trade Commission
Queensland Health
Johnson and Johnson
Harvard Business School
Fuji
Boehringer Ingelheim
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot